Citations

Showing 10 of 108081 citations.

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials
Yan, Fangrong , Mandrekar, Sumithra J. , Yuan, Ying

Mayo Clinic

Clinical Cancer Research | May 25, 2017 | Volume: 23 | Issue: 15 | Pages: 3994-4003

10.1158/1078-0432.ccr-17-0220 | PMID 28546227 Get It

Abstract The primary objective of phase I oncology trials is to find the MTD. The 3+3 design is easy to implement but performs poorly in finding the MTD. A newer design, such as the modified toxicity probability interval (mTPI) design, provides better accuracy to identify the MTD but tends to overdose patients. We propose the keyboard design, an intuitive Bayesian design that conducts dose escalation and de-escalation based on whether the strongest key, defined as the dosing interval that most likely contains the current dose, is below or above the target dosing interval. The keyboard design can be implemented in a simple way, similar to the traditional 3+3 design, but provides more flexibility for choosing the target toxicity rate and cohort size. Our simulation studies demonstrate that compared with the 3+3 design, the keyboard design has favorable operating characteristics in terms of identifying the MTD. Compared with the mTPI design, the keyboard design is safer, with a substantially lower risk of treating patients at overly toxic doses, and has the better precision to identify the MTD, thereby providing a useful upgrade to the mTPI design. Software freely available at http://www.trialdesign.org facilitates the application of the keyboard design. Clin Cancer Res; 23(15); 3994–4003. ©2017 AACR. See related commentary by Paoletti et al., p. 3977
Automated low‐contrast pattern recognition algorithm for magnetic resonance image quality assessment
Ehman, Morgan O., Bao, Zhonghao , Stiving, Scott O., Kasam, Mallikarjunarao , Lanners, Dianna , Peterson, Teresa, Jonsgaard, Renee , Carter, Rickey E. , McGee, Kiaran P. , Kasam, Mallik, Carter, Rickey, Carter, Rickey E

Mayo Clinic

Medical Physics | May 25, 2017 | Volume: 44 | Issue: 8 | Pages: 4009-4024

10.1002/mp.12370 | PMID 28543961 Get It

PurposeLow contrast (LC) detectability is a common test criterion for diagnostic radiologic quality control (QC) programs. Automation of this test is desirable in order to reduce human variability and to speed up analysis. However, automation is challenging due to the complexity of the human visual perception system and the ability to create algorithms that mimic this response. This paper describes the development and testing of an automated LC detection algorithm for use in the analysis of magnetic resonance (MR) images of the American College of Radiology (ACR) QC phantom.MethodsThe detection algorithm includes fuzzy logic decision processes and various edge detection methods to quantify LC detectability. Algorithm performance was first evaluated using a single LC phantom MR image with the addition of incremental zero mean Gaussian noise resulting in a total of 200 images. A c‐statistic was calculated to determine the role of CNR to indicate when the algorithm would detect ten spokes. To evaluate inter‐rater agreement between experienced observers and the algorithm, a blinded observer study was performed on 196 LC phantom images acquired from nine clinical MR scanners. The nine scanners included two MR manufacturers and two field strengths (1.5 T, 3.0 T). Inter‐rater and algorithm‐rater agreement was quantified using Krippendorff's alpha.ResultsFor the Gaussian noise added data, CNR ranged from 0.519 to 11.7 with CNR being considered an excellent discriminator of algorithm performance (c‐statistic = 0.9777). Reviewer scoring of the clinical phantom data resulted in an inter‐rater agreement of 0.673 with the agreement between observers and algorithm equal to 0.652, both of which indicate significant agreement.ConclusionsThis study demonstrates that the detection of LC test patterns for MR imaging QC programs can be successfully developed and that their response can model the human visual detection system of expert MR QC readers.
Sex differences in fitness and cardiac function during exercise in adolescents with chronic fatigue
Pianosi, Paolo T. , Emerling, Eric, Mara, Kristin C. , Weaver, Amy L. , Pianosi, P T , Fischer, Philip R. , Mara, Kristin C

Mayo Clinic

Scandinavian Journal of Medicine & Science in Sports | May 25, 2017 | Volume: 28 | Issue: 2 | Pages: 524-531

10.1111/sms.12922 | PMID 28543923 Get It

Females demonstrate less robust Frank‐Starling mechanism with respect to cardiac preload than males at rest. We asked whether this phenomenon would also affect cardiac performance during exercise. We hypothesized that stroke volume (SV) response to exercise would be more limited in deconditioned females such that cardiac output would be mainly rate dependent, compared with males. We conducted a chart audit of clinical exercise tests performed by adolescents with chronic fatigue. Oxygen uptake () was measured breath‐by‐breath at rest and during cycle ergometry, while cardiac output was measured by acetylene rebreathing at rest plus 2‐3 subthreshold workloads. SV response was analyzed in two ways: after normalization for body surface area (SV index, SVI) and as percentage change from resting values. Among 304 adolescents (78% females) with chronic fatigue, 189 (80%) of 236 females and 52 (76%) of 68 males were deconditioned (peakO2 <90% predicted). Heart rate trajectory during exercise was steeper for unfit than fit females, 70 vs 61 beat·min−1 per L·min−1 , (P=.003); but not for males, 47 vs 42 beat·min−1 per L·min−1 (P=.23). The highest measured SVI did not differ between unfit vs fit females (42.8 vs 41.5 mL·m−2, P=.39) while fit males showed larger SV during exercise than their unfit peers (highest SVI 55.9 vs 48.0 mL·m−2, P=.014). Both qualitative and quantitative sex differences exist in SV responses to exercise among chronically fatigued adolescents, suggesting volume loading may be more efficacious in girls.
Right ventricular pacemaker lead position is associated with differences in long‐term outcomes and complications
Witt, Chance M. , Lenz, Charles J., Shih, Henry, Ebrille, Elisa , Rosenbaum, Andrew , Zyl, Martin van , Aung, Htin , Manocha, Kevin K. , Deshmukh, Abhishek , Hodge, David O. , Mulpuru, Siva K. , Cha, Yong‐Mei , Espinosa, Raúl E. , Asirvatham, Samuel J. , McLeod, Christopher J. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 25, 2017 | Volume: 28 | Issue: 8 | Pages: 924-930

10.1111/jce.13256 | PMID 28543771 Get It

AbstractIntroductionCardiac pacing from the right ventricular apex is associated with detrimental long‐term effects and nonapical pacing locations may be associated with improved outcomes. There is little data regarding complications with nonapical lead positions. The aim of this study was to assess long‐term outcomes and lead‐related complications associated with differing ventricular lead tip position.Methods and resultsAll adult patients who underwent dual‐chamber pacemaker implantation from 2004 to 2014 were included if they had postprocedure chest radiographs amenable to lead position determination. Long‐term outcomes and lead‐related complication rates were recorded. These were compared at 5 years between: (1) apical and septal leads, (2) apical and nonseptal nonapical (NSNA), and (3) apical and septal with >40% ventricular pacing. We retrospectively evaluated 3,450 patients, which included 238 with a septal position and 733 with NSNA lead positions. Septal lead position was associated with a lower mortality compared to apical leads (24% vs. 31%, P = 0.02). In patients with greater than 40% pacing, septal leads were associated with significantly higher rates of incident atrial fibrillation compared to apical leads (49% vs. 34%, P = 0.04). NSNA positions were associated with a significantly higher rate of lead dislodgement (4% vs. 2%, P = 0.005) and need for revision (8% vs. 5%, P = 0.005).ConclusionsSeptal pacemaker lead position is associated with a lower mortality compared to apically placed leads, but a higher incidence of atrial fibrillation with higher percentage ventricular pacing. NSNA lead locations are associated with more complications and should be avoided.
Nanotherapeutic systems for local treatment of brain tumors
Chakroun, Rami W. , Zhang, Pengcheng , Lin, Ran , Schiapparelli, Paula , Quiñones‐Hinojosa, Alfredo , Cui, Honggang

Mayo Clinic

WIREs Nanomedicine and Nanobiotechnology | May 25, 2017 | Volume: 10 | Issue: 1 | Pages: No page available

10.1002/wnan.1479 | PMID 28544801 Get It

Malignant brain tumor, including the most common type glioblastoma, are histologically heterogeneous and invasive tumors known as the most devastating neoplasms with high morbidity and mortality. Despite multimodal treatment including surgery, radiotherapy, chemotherapy, and immunotherapy, the disease inevitably recurs and is fatal. This lack of curative options has motivated researchers to explore new treatment strategies and to develop new drug delivery systems (DDSs); however, the unique anatomical, physiological, and pathological features of brain tumors greatly limit the effectiveness of conventional chemotherapy. In this context, we review the recent progress in the development of nanoparticle‐basedDDSsaiming to address the key challenges in transporting sufficient amount of therapeutic agents into the brain tumor areas while minimizing the potential side effects. We first provide an overview of the standard treatments currently used in the clinic for the management of brain cancers, discussing the effectiveness and limitations of each therapy. We then provide an in‐depth review of nanotherapeutic systems that are intended to bypass the blood–brain barrier, overcome multidrug resistance, infiltrate larger tumorous tissue areas, and/or release therapeutic agents in a controlled manner.WIREs Nanomed Nanobiotechnol2018, 10:e1479. doi: 10.1002/wnan.1479This article is categorized under:Implantable Materials and Surgical Technologies > Nanomaterials and ImplantsTherapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Ileocecal vascularized lymph node transfer for the treatment of extremity lymphedema: A case report
Ciudad, Pedro , Manrique, Oscar J. , Agko, Mouchammed , Liu, En‐Wei , Chang, Wei‐Ling , Yeo, Matthew Sze‐Wei , Huang, Tony Chieh‐Ting , Chilgar, Ram M., Chen, Hung‐Chi , Chen, Hung‐Chi , Mouchammed, Agko , Huang, Tony C T

Mayo Clinic

Microsurgery | May 25, 2017 | Volume: 39 | Issue: 1 | Pages: 81-84

10.1002/micr.30186 | PMID 28543381 Get It

Vascularized lymph node (VLN) transfer has been of high interest in the past decade for the treatment of lymphedema, since it has been shown to be effective in reducing limb volumes, decreasing infectious episodes and improving quality of life. Multiple donor sites have been described in the quest for the optimal one. Herein, we describe a novel lymph node flap option based on the ileocolic artery and vein. The ileocecal vascularized lymph node (IC‐VLN) flap was used in the management of a 33‐year‐old male patient with lower extremity lymphedema secondary to left inguinal trauma. The patient had previously underwent a pedicled omentum flap transposition with minimal improvement in limb size and persistent episodes of infection. At 15 month follow‐up, the IC‐VLN flap improved the lymphatic drainage in the affected limb with a mean limb circumference reduction rate of 26.3%. No donor site complications or further episodes of infection were noted. According to our findings, the IC‐VLN flap may be another option for VLN transfer in very selected cases. Nevertheless, larger series with a longer follow‐up are required to analyze the efficacy and long‐term results of this flap.
When Should Emergent Imaging Be Performed?—Reply
Chen, John J. , Fang, Chengbo , Leavitt, Jacqueline A., Chen, John J

Mayo Clinic

JAMA Ophthalmology | May 25, 2017 | Volume: 135 | Issue: 7 | Pages: 820

10.1001/jamaophthalmol.2017.1430 | PMID 28542672 Get It

Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number
Eirin, Alfonso , Saad, Ahmed , Woollard, John R. , Juncos, Luis A. , Calhoun, David A. , Textor, Stephen C., Lerman, Lilach O. , Tang, Hui Jun , Lerman, Amir , Eirin, Alfonso , Juncos, Luis A

Mayo Clinic

American Journal of Hypertension | May 25, 2017 | Volume: 30 | Issue: 11 | Pages: 1112-1119

10.1093/ajh/hpx103 | PMID 28641368 Get It

Endoscopic management of bile leaks after liver transplantation: An analysis of two high-volume transplant centers
Sendino, Oriol , Fernández-Simón, Alejandro , Law, Ryan , Dayyeh, Barham Abu, Leise, Michael D. , Chavez-Rivera, Karina, Córdova, Henry , Colmenero, Jordi , Crespo, Gonzalo , Miguel, Cristina Rodríguez de , Fondevila, Constantino , Llach, Josep, Navasa, Miquel , Baron, Todd H. , Abu Dayyeh, Barham, Leise, Michael, Llach, Josep, Cárdenas, Andrés , Crespo, Gonzalo , Colmenero, Jordi

Mayo Clinic

United European Gastroenterology Journal | May 25, 2017 | Volume: 6 | Issue: 1 | Pages: 89-96

10.1177/2050640617712869 | PMID 29435318 Get It

Background Bile leak after liver transplantation (LT) is commonly treated with endoscopic retrograde cholangiopancreatography (ERCP); however, there are limited data regarding the optimal treatment strategy. Objective We aimed to examine the role of ERCP in LT recipients with bile leaks at two large institutions. Methods We reviewed all ERCPs performed in LT recipients with bile leak and duct-to-duct biliary anastomosis at two high-volume transplant centers. Results Eighty patients were included. Forty-seven (59%) patients underwent ERCP with plastic stent placement (with or without sphincterotomy) and 33 patients (41%) underwent sphincterotomy alone. Complete resolution was obtained in 94% of the stent group vs. 58% of the sphincterotomy group ( p < 0.01). There was no difference in three-month survival among both groups. Percutaneous transhepatic therapy and surgery were required in 4% and 6% in the stent group vs. 12% and 42% in the sphincterotomy group, respectively ( p = 0.22 and p < 0.001). The only predictive factor of bile leak resolution was stent placement. Conclusion ERCP with plastic stent placement is highly successful and more effective than sphincterotomy alone for post-LT bile leak treatment. These results indicate that ERCP and plastic stent placement should be considered the standard of care for the treatment of bile leaks in LT.
TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling
Masyuk, Anatoliy I. , Pisarello, María J. Lorenzo , Howard, Brynn N., Huang, Bing , Lee, Pui Yuen , Sergienko, Eduard , Ardecky, Robert, Chung, Thomas D.Y. , Pinkerton, Anthony B. , Masyuk, Tatyana V. , Lorenzo Pisarello, Maria, Huang, Bing Q, Fung, Xavier, Fung, Xavier C. C. , LaRusso, Nicholas F.

Mayo Clinic

Hepatology | May 25, 2017 | Volume: 66 | Issue: 4 | Pages: 1197-1218

10.1002/hep.29284 | PMID 28543567 Get It

Hepatic cystogenesis in polycystic liver disease is associated with increased levels of cyclic adenosine monophosphate (cAMP) in cholangiocytes lining liver cysts. Takeda G protein receptor 5 (TGR5), a G protein–coupled bile acid receptor, is linked to cAMP and expressed in cholangiocytes. Therefore, we hypothesized that TGR5 might contribute to disease progression. We examined expression of TGR5 and Gα proteins in cultured cholangiocytes and in livers of animal models and humans with polycystic liver disease. In vitro, we assessed cholangiocyte proliferation, cAMP levels, and cyst growth in response to (1) TGR5 agonists (taurolithocholic acid, oleanolic acid [OA], and two synthetic compounds), (2) a novel TGR5 antagonist (m‐tolyl 5‐chloro‐2‐[ethylsulfonyl] pyrimidine‐4‐carboxylate [SBI‐115]), and (3) a combination of SBI‐115 and pasireotide, a somatostatin receptor analogue. In vivo, we examined hepatic cystogenesis in OA‐treated polycystic kidney rats and after genetic elimination of TGR5 in double mutant TGR5−/− ;Pkhd1del2/del2 mice. Compared to control, expression of TGR5 and Gαs (but not Gαi and Gαq) proteins was increased 2‐fold to 3‐fold in cystic cholangiocytes in vitro and in vivo. In vitro, TGR5 stimulation enhanced cAMP production, cell proliferation, and cyst growth by ∼40%; these effects were abolished after TGR5 reduction by short hairpin RNA. OA increased cystogenesis in polycystic kidney rats by 35%; in contrast, hepatic cystic areas were decreased by 45% in TGR5‐deficient TGR5−/−;Pkhd1del2/del2 mice. TGR5 expression and its colocalization with Gαs were increased ∼2‐fold upon OA treatment. Levels of cAMP, cell proliferation, and cyst growth in vitro were decreased by ∼30% in cystic cholangiocytes after treatment with SBI‐115 alone and by ∼50% when SBI‐115 was combined with pasireotide. Conclusion: TGR5 contributes to hepatic cystogenesis by increasing cAMP and enhancing cholangiocyte proliferation; our data suggest that a TGR5 antagonist alone or concurrently with somatostatin receptor agonists represents a potential therapeutic approach in polycystic liver disease. (Hepatology 2017;66:1197‐1218).